Proactive Investors - Run By Investors For Investors

Actinogen Medical raises $10M for Alzheimer’s drug trial

Actinogen Medical raises $10M for Alzheimer’s drug trial

Sydney based Actinogen Medical (ASX:ACW) has raised $10.0 million to further a trial of its very promising drug to fight Alzheimer’s disease.

The funds were raised in a placement which saw heavy investor demand at an issue price of $0.095 per share.

The Phase 2 trial of its drug Xanamem™ is planned to start in 2016 and for it to run in Australia/New Zealand, the USA and the UK.

Xanamem blocks cortisol production which is a key plank in the fight against Alzheimer's disease to stop the disease at an early stage.

Excess cortisol is associated with memory loss and amyloid plaques, hallmarks of Alzheimer’s disease.

The capital raising will also be used to support the IND filing with US FDA.

A share purchase plan will also raise an additional $1 million.

Alzheimer’s disease is the most common form of dementia and has a debilitating effect on patients and families. At present, there is no viable cure for sufferers.

Alzheimer’s is now the second leading cause of death in Australia behind ischaemic heart disease.

Estimates by the American Alzheimer’s Association indicate that the direct healthcare cost of the disease was $US250 billion in 2013.

This is projected to rise to over $US1 trillion by 2050, outstripping the cost of treating all other diseases.

 

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

View full ACW profile View Profile

Actinogen Medical Ltd Timeline

Newswire
December 30 2016

Related Articles

cancer
February 26 2019
Immunotherapy treatment Clevegen is on phase I/II trial (MATINS) for metastatic tumours
Once the phase III trial is completed, Futura plans to either sell off the asset or find a partner
September 26 2018
The pharma group expects to dose the first patient in the Phase III trial of its MED2002 erectile dysfunction treatment within the next month
Empty lab
September 19 2018
Management has made some tough decisions, cutting the cost base, since a disappointing first-half performance and expects the benefits to really kick in next year

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use